Skip to main content
. 2014 Apr 11;28(5):538–545. doi: 10.1038/eye.2014.64

Table 2. Linear regression analysis of prognostic factors.

  Beta value Power
Intercept +0.09±0.20 0.65
Age (in years) +0.001±0.002 0.64
Switch to bevacizumab/ranibizumab +0.03±0.05 0.53
Visual acuity before switch (log10) +0.19±0.08 0.02
Change of visual acuity before switch −0.10±0.10 0.30
Macular thickness before switch (in μm) <−0.001±<0.001 0.14
Stratus/Spectralis OCT −0.04±0.05 0.38